AnaptysBio, Inc.
ANAB • NASDAQ
AnaptysBio, Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Daniel R. Faga, with a market cap of $1.3B.
CEODaniel R. Faga
Market Cap$1.3B
Biotechnology
Healthcare
Employees117.0
Websiteanaptysbio.com
Country
United States of America
Next Earnings
Upcoming earnings announcement for AnaptysBio, Inc.
Date
Monday, May 4, 2026 (in 3 months)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$1.10
Revenue Estimate
$24.0M
Earnings History
Past 11 earnings reports for AnaptysBio, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Nov 4, 2025 | Q3 2025 | $0.52Est: -$1.17 | +144.4% | $76.3MEst: $25.6M | +198.7% |  10-Q |
| Aug 6, 2025 | Q2 2025 | -$1.34Est: -$1.55 | +13.5% | $22.3MEst: $13.5M | +64.7% | 10-Q |
| May 5, 2025 | Q1 2025 | -$1.28Est: -$1.46 | +12.3% | $27.8MEst: $15.3M | +81.9% | 10-Q |
| Feb 27, 2025 | Q4 2024 | -$0.72Est: -$1.74 | +58.6% | $43.1MEst: $10.1M | +327.3% | 10-K |
| Nov 5, 2024 | Q3 2024 | -$1.14Est: -$1.65 | +30.9% | $30.0MEst: $6.9M | +336.7% | 10-Q |
| Aug 5, 2024 | Q2 2024 | -$1.71Est: -$0.89 | -92.1% | $11.0MEst: $24.3M | -54.9% | 10-Q |
| May 9, 2024 | Q1 2024 | -$1.64Est: -$1.56 | -5.1% | $7.2MEst: $3.7M | +93.0% | 10-Q |
| Mar 11, 2024 | Q4 2023 | -$1.59Est: -$1.60 | +0.6% | $9.0MEst: $2.2M | +303.8% | 10-K |
| Nov 2, 2023 | Q3 2023 | -$1.41Est: -$1.79 | +21.2% | $3.3MEst: $2.5M | +32.2% | — |
| Aug 7, 2023 | Q2 2023 | -$1.50Est: -$1.70 | +11.8% | $3.5MEst: $3.3M | +4.2% | 10-Q |
| May 11, 2023 | Q1 2023 | -$1.58Est: -$1.05 | -50.5% | $1.4MEst: $3.6M | -61.5% | 10-Q |